Marquette Asset Management LLC grew its stake in Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Rating) by 7.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 38,000 shares of the company’s stock after buying an additional 2,500 shares during the period. Marquette Asset Management LLC’s holdings in Chinook Therapeutics were worth $665,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Samsara BioCapital LLC increased its stake in shares of Chinook Therapeutics by 36.0% in the fourth quarter. Samsara BioCapital LLC now owns 4,591,888 shares of the company’s stock worth $74,894,000 after purchasing an additional 1,215,000 shares during the period. BlackRock Inc. increased its stake in shares of Chinook Therapeutics by 2.2% in the first quarter. BlackRock Inc. now owns 3,054,997 shares of the company’s stock worth $49,980,000 after purchasing an additional 67,066 shares during the period. Deep Track Capital LP increased its stake in shares of Chinook Therapeutics by 23.9% in the first quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock worth $49,080,000 after purchasing an additional 579,498 shares during the period. Frazier Life Sciences Management L.P. bought a new position in shares of Chinook Therapeutics in the first quarter worth about $44,369,000. Finally, Point72 Asset Management L.P. increased its stake in shares of Chinook Therapeutics by 136.4% in the fourth quarter. Point72 Asset Management L.P. now owns 2,351,743 shares of the company’s stock worth $38,357,000 after purchasing an additional 1,356,873 shares during the period.
Insider Activity at Chinook Therapeutics
In other news, insider Andrew James King sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, July 11th. The stock was sold at an average price of $18.09, for a total value of $90,450.00. Following the sale, the insider now directly owns 5,897 shares in the company, valued at approximately $106,676.73. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 23.38% of the company’s stock.
Analyst Upgrades and Downgrades
Chinook Therapeutics Trading Down 3.4 %
KDNY traded down $0.67 on Friday, hitting $18.99. 577,271 shares of the stock traded hands, compared to its average volume of 515,776. Chinook Therapeutics, Inc. has a 52 week low of $10.48 and a 52 week high of $23.86. The business has a fifty day moving average price of $20.48 and a two-hundred day moving average price of $17.39.
Chinook Therapeutics (NASDAQ:KDNY – Get Rating) last issued its quarterly earnings results on Monday, August 8th. The company reported ($0.61) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.61). Chinook Therapeutics had a negative return on equity of 22.18% and a negative net margin of 170.15%. As a group, research analysts predict that Chinook Therapeutics, Inc. will post -2.47 earnings per share for the current year.
Chinook Therapeutics Company Profile
Chinook Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases.
- Get a free copy of the StockNews.com research report on Chinook Therapeutics (KDNY)
- Why Does Tesla Stock Remain Resilient?
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
- 2 Semiconductor Stocks To Watch For Reversals
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
Receive News & Ratings for Chinook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chinook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.